5 notes on departing Sanofi Genzyme executive Dr. David Meeker & his next steps

Listen
Text
  • Small
  • Medium
  • Large

David Meeker, MD, is stepping down from Cambridge, Mass.-based Sanofi Genzyme at the end of June 2017 as the company's executive vice president and head, according to the Boston Globe.

Here are five notes:

1. Bill Sibold will take over for Dr. Meeker. Mr. Sibold is currently leading the company's oncology and immunology programs.

2. Dr. Meeker hired Mr. Sibold in 2011 to create and build up Sanofi Genzyme's multiple sclerosis business.

3. During Dr. Meeker's tenure, Sanofi Genzyme developed its first multiple sclerosis medicines, Aubagio and Lemtrada. The company recently obtained US approval to market Dupixent, a drug to treat eczema.

4. He told the Boston Globe his greatest achievement was strengthening the company's multiple sclerosis franchise and maintaining the culture of putting the patient first and being a "science-driven company."

5. Dr. Meeker is weighing options for his next career move. He told the Boston Globe, "I'm more excited by the industry than ever. And I look forward to being an active contributor."

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast